Introduction
Growth, development and dierentiation of mammary epithelial tissues are multi-stage processes that are driven by a combination of autocrine systemic ovarian and pituitary hormones as well as paracrine signaling factors Spitzer et al., 1995) . There is increasing evidence that genetic alterations in growth factor signaling pathways are closely related to developmental abnormalities and to chronic diseases including cancer (Aaronson et al., 1991; Yee et al., 1989) . The EGFR is a member of the type I receptor tyrosine kinase family (RTK) (Hackel et al., 1999) and can be stimulated upon autocrine and/or paracrine interactions with corresponding ligands such as EGF, transforming growth factor alpha (TGFa) and amphiregulin (Normanno et al., 1995) . Overexpression of the EGFR is associated with enhanced metastatic potential in experimental studies, and poor prognosis in human breast cancer (Harris and Nicholson 1987; Klijn et al., 1992) . The EGFR is overexpressed in about 48% of primary human breast tumors (Klijn et al., 1992) . Cellular transformation mediated by ligand activation of the EGFR has been experimentally demonstrated in rodent ®broblasts transfected with the EGFR and mammary epithelial cells following the constitutive overproduction of EGF or TGFa (Di Fiore et al., 1987a; Tortora et al., 1989) .
Therefore, it has been concluded that EGFR can facilitate cellular transformation. An increase in TGFa synthesis and secretion generally occurs in several types of human carcinoma cell lines, in primary human tumors and in ®broblasts or in mammary epithelial cell lines that have been transformed with a number of dierent oncogenes such as point mutated c-Ha-or Kiras genes (Di Marco et al., 1989; Salomon et al., 1991) . Furthermore, blocking EGFR expression by introducing an EGFR antisense construct or treating cells with an EGFR neutralizing antibody inhibits colony formation in semisolid medium as well as growth of tumors cells as xenografts in nude mice (Baselga and Mendelsohn, 1994; Chakrabarty et al., 1995; Fan et al., 1993; Liu et al., 1995; Rajagopal et al., 1995) .
Transgenic mice represent a useful model to assess tissue speci®c action of oncogenes or growth factors in vivo and to study their role in breast cancer formation (Hinrichs et al., 1991) . Transgenic mice expressing various oncogenes speci®cally in the mammary gland have been generated by employing either the mouse mammary tumor virus (MMTV)-LTR, or milk protein speci®c promoters such as the whey acidic protein, b-lactalbumin or b-lactoglobulin promoters (for review see Muller, 1991) . In the majority of these cases, mammary tumors develop in a stochastic fashion with a latency period of 5 ± 10 months (Andres et al., 1988; Bouchard et al., 1989; Goldenring et al., 1993; Krane and Leder, 1996) . These data suggest that overexpression of individual oncogenes is necessary but not sucient for tumor induction. Additional secondary genetic events are likely to contribute to the tumor phenotype. In this respect, mammary gland speci®c TGFa overexpression leads to the development of mammary adenocarcinomas that also exhibit an increase in EGFR expression, supporting the hypothesis of an autocrine mechanism for transformation of the mammary epithelium by the EGFR (Matsui et al., 1990) . Therefore an increase in the expression of the EGF-receptor and/or its ligands in mammary tissue might be a primary cause for tumor formation. However, direct experimental validation of whether EGFR overexpression can contribute to mammary tumorigenesis is lacking.
To address this question we generated transgenic mouse lines expressing the hEGFR under the control of two mammary gland directed promoters and studied mammary gland growth and functional dierentiation in vivo as well as in vitro. We demonstrate that hEGFR expression can cause hyperplastic, dysplastic and neoplastic changes in mammary epithelia of transgenic mice. By employing whole mount mammary gland organ culture, we found that the expression of the hEGFR suppresses functional and morphological dierentiation of the mouse mammary epithelium.
Results

Generation of transgenic mice
To directly investigate the role of EGFR overexpression in growth, development and tumorigenesis of the mammary gland, we created transgenic mice expressing the hEGFR under the mammary gland speci®c control of the MMTV/LTR or the b-lactoglobulin (BLG) promoter. Two hybrid genes, the MMTV-HERc-SV40 polyA + (MHERc) and the b-lactoglobulin-HERc (BLGHERc) were constructed (Figure 1a,c) . In addition to the 5'-and 3'-untranslated regions of the blactoglobulin gene, the expression cassette contains a truncated exon/intron sequences of this gene ( Figure  1b) . The human EGFR BLGHERc expression construct was co-injected with the complete sheep blactoglobulin gene containing an in-frame mutation to generate a premature translational stop (Figure 1b,c) , preventing BLG synthesis. Co-injection of these two constructs results in co-integration of both cDNA's into the mouse genome and should stabilize the hEGFR mRNA (Yull et al., 1996) . Transgenic mice were identi®ed by PCR analysis by employing speci®c hEGFR primers. hEGFR positive mice were further veri®ed by Southern blot analysis using a hEGFR speci®c 1.1 kb DNA probe (data not shown). DNA from BLGHERc positive mice was additionally analysed by PCR detecting a DNA sequence of the ®rst exon of the sheep BLG sequence not present in the BLGHERc expression construct. All BLGHERc founder mice were shown to be bitransgenic for both the BLGHERc expression construct and the silent b-lactoglobulin gene. For both the MHERc and the BLGHERc expression construct we identi®ed two founder mice which were used to generate four independent transgenic lines: line 6903 and line 7343 for the MHERc strain and line 28 and line 116 for the BLGHERc strain.
Females of both the MHERc and the BLGHERc strains were able to wean their osprings. Males of one MHERc strain (line 7343) were infertile.
Expression analysis
hEGFR transgene expression was analysed by RT ± PCR (Table 1 ). The speci®city of the RT ± PCR reaction for the transgene was con®rmed by using total RNA from wild type liver expressing high amounts of endogenous mouse EGFR mRNA which yielded no ampli®cated product. hEGFR mRNA was expressed in mammary glands of both virgin and lactating animals from the MHERc strains. Compared to lactating animals approximately 10 times more mRNA had to be used for RT ± PCR to detect transgene expression in virgin MHERc mice (data not shown). In addition, transgene expression was observed in testis, ovary and male salivary gland. No transgene expression was found in male mammary gland of MHERc mice, in uterus and in liver (Table 1) . For the BLGHERc strains, a dierent expression pattern of the transgene was observed. hEGFR mRNA was expressed only in the lactating mammary gland which generated a strong RT ± PCR signal. No other organ was found positive for the transgene expression (Table 1) . Highest expression was found in tumor tissue as shown by Northern analysis (Figure 2a ) and immunohistochemistry ( Figure 5 ).
Whole mount mammary gland preparations
To gain more information about the in¯uence of EGFR overexpression on phenotypic dierences between wild type and transgenic animals, mammary gland whole-mount preparations were made ( Figure  2c,d) . The mammary tree of the transgenic animals was grossly abnormal (Figure 2d ). They showed enlarged ducts and multiple hyperplastic alveolar nodules, whereas the wild type glands appeared normal ( Figure  2c ).
Mammary histology of virgin mice Histological examination revealed that mammary glands of control virgin mice aged 6 ± 12 weeks consist of adipose tissue surrounding small ducts lined with unilayered cuboid epithelial cells. These ducts are surrounded by myoepithelial cells and connective tissue (Figure 3a1 ). In contrast, both MHERc and BLGHERc transgenic virgin mice of the same age showed scattered clusters of small ducts lined by multilayered cuboidal epithelium and myoepithelium (Figure 3b, c) . Although the diameter was similar to the ducts of control mice (Figure 3a1 ), the lumens of ducts evaluated in glands obtained from MHERc mice were not always apparent as they were occluded with epithelial cells (Figure 3b ). In the virgin hEGFR transgenic mice, the number of ductal clusters per microscopic ®eld (36+4) exceeded that of control nontransgenic mice (15+5, compare to Figure 3a1 ). Enhanced proliferative activity (more than twofold) of the epithelium as evidenced by PCNA staining was observed for the transgenic MHERc virgin mice (Figure 4 ). These data demonstrate an increased proliferation rate of the mammary epithelium found in virgin MHERc and BLGHERc transgenic mice. Furthermore, the ductal epithelium in glands of virgin MHERc mice was multilayered, probably corresponding to a higher mitotic index as assessed by PCNA labeling (Figure 4 ).
Mammary histology of lactating mice
The majority of lactating mammary glands from both MHERc and BLGHERc transgenic mice after three pregnancies exhibited glandular epithelial tissue corresponding to that of the control mice ( Figure 3d ). However, an Figure 2 Northern blot analysis of mammary gland tissue and whole mount stainings. (a) 15 mg total RNA from transgenic mammary glands with hyperplastic nodules (#2254, #1746), a mammary gland tumor (#2252) and a wild type mammary gland. The blot was hybridized to a hEGFR speci®c cDNA probe and the transgene-speci®c mRNAs are indicated by an arrow. (b) The same blot as in a was hybridized to a GAPDH speci®c cDNA probe as a loading control. (c) Carmine-red stained mammary gland preparation from a wild type female mouse. (d) Carmine-red stained mammary gland preparation from a transgenic female mouse of the BLGHERc strain overall increase in epithelial cell proliferation within lobules was observed in multilayered lobular hyperplastic and dysplastic epithelial ducts ( Figure 3e ,f, compare to the control represented in Figure 3d ). Mammary glands were obtained from hEGFR transgenic mice on days 5, 10 and 16 of lactation after up to four pregnancies. In some lobules the transgenic mammary epithelium was multilayered and the typical cuboidal morphology of these cells was lost with cells being packed in clusters (Figure 3e ). Regressed
MHERc mammary gland showed a similar histology as the virgin gland ( Figure 3a2 ). The MHERc and BLGHERc strains exhibited a similar histology in the lactating mammary gland. In both transgenic strains, the number of poorly dierentiated areas and areas consisting of multilayered lobular epithelium increased with the number of pregnancies. In addition, the number of cells located within the poorly dierentiated clusters was increased with the number of pregnancies, which correlates with the high proliferation index in these areas. In one out of six multiparous BLGMHERc and in two out of six multiparous MHERc transgenic mice exhibiting dysplasia, small tubular adenocarcinomas were found (Figure 3g ,h,i). The tumors exhibited nuclear anisomorphy and showed only irregular separation from adjacent non-carcinoma tissue.
Immunohistochemistry
Elevated hEGFR expression was detected in transgenic mammary glands, as evidenced by enhanced immunohistochemical staining of the epithelial cells within the ducts (Figure 5b ± d) . hEGFR expression in these regions was heterogeneous localized in discrete cellular clusters. In addition histological samples contained areas, which consisted of small ducts with unilayered epithelium surrounded by myoepithelium (Figure 5e ). These regions appeared to resemble non-dierentiated resting lobules with lower proliferation index of approximately 30 ± 50% that had been counted by Figure 4 Labeling index of mammary epithelial cells of hEGFR virgin transgenic and control mice. Labeling index was determined by analysing PCNA expression using a anti-PCNA speci®c antibody. Each bar represents the average number of mitotic cells counted in ®ve independent microscopic ®elds immunohistochemical proliferation cell nuclear antigen (PCNA) detection (data not shown). In these areas hEGFR expression was higher than in normal dierentiated areas of the mammary gland where no immunostaining was detected (Figure 5e ). The adenocarcinomas were characterized by high hEGFR expression as demonstrated by immunohistochemistry (Figure 5f ) and northern analysis (Figure 2a) .
Whole mount organ cultures of mammary glands
To ascertain whether hEGFR overexpression might in¯uence mammary epithelial dierentiation, whole mount organ cultures of the second thoracic mammary gland were obtained from progesterone and estradiol primed 4 ± 6 week-old virgin female transgenic or control mice. To induce mammary gland dierentiation in vitro mammary glands were cultured in a lactogenic hormone mixture, containing aldosterone, prolactin, insulin and hydrocortisone (APIH). Glands obtained from control mice that were cultured for 7 days in APIH medium developed ducts which terminated in lobuli consisting of fully developed alveoli (Figure 6a ). However, mammary glands cultured in medium, containing aldosterone and insulin (AI-medium), developed ducts with little branching (data not shown). Functional dierentiation was analysed by assessing whey acidic protein (WAP)-mRNA expression by Northern blot analysis (Figure 7 ). Control glands cultured in AI-medium did not express WAP (data not shown) whereas APIH-medium induced WAP expression ( Figure 7, lane 1) . The addition of EGF to the lactogenic APIH-medium decreased branching of the ducts and development of alveoli whereas the number of ducts was comparable to that in glands cultured in lactogenic medium without EGF ( Figure  6b ). In these EGF treated glands, WAP expression was down regulated (Figure 7, lane 2) .
Mammary glands were obtained from both MHERc and BLGHERc transgenic virgin mice and cultured in lactogenic APIH-medium. These glands had reduced numbers of secondary ducts and alveoli (Figure 6c,d) . Little morphological dierentiation of these glands was observed. Only main ducts showing a few branches containing short secondary ducts with a few immature lobulo-aveolar structures developed (Figure 6c,d) . The morphology of these undierentiated glands was identical to glands obtained from nontransgenic mice that had been cultured in APIH-lactogenic medium containing EGF (compare to Figure 6b) . Furthermore, functional dierentiation as assessed by WAP mRNA expression was inhibited. WAP expression is impeded in both MHERc and BLGHERc transgenic glands after 7 days of culture (Figure 7, lanes 3, 4) . Adding Figure 6 Dierentiation study of the mammary gland using whole mount organ culture obtained from transgenic and control mice. Second thoracic mammary gland of transgenic and control mice were cultured for 7 days under dierent medium conditions. (a) Control gland cultured in lactogenic APIH-medium. (b) Control gland cultured in lactogenic APIH-medium in the presence of 10 ng/ml mEGF, note that morphologic dierentiation is strongly inhibited. Both MHERc (c, line 6903) and BLGHERc (d, line 116) transgenic glands are cultured in lactogenic APIH-medium, note the complete reduction of alveoli and only poor branching of the main ducts EGF to the lactogenic APIH-medium did not lead to further inhibition of functional and morphological dierentiation (data not shown) suggesting that hEGFR overexpression is sucient to block functional and morphological dierentiation of the mammary gland.
Discussion
Several lines of evidence suggest an oncogenic role for the EGF-receptor in mammary tumors. EGFR overexpression could be a primary event in inducing transformation or a secondary modi®cation facilitating growth and transformation, which had been demonstrated in in vitro systems (Di Fiore et al., 1987b) . Together with other genetic alterations such as c-erbB-2 overexpression or estrogen receptor status, EGFR overexpression, due in large part to gene ampli®cation, correlates with a poor prognosis for overall patient survival (Al-Kasspooles et al., 1993; Borg et al., 1991; Fox et al., 1994; Gramlich et al., 1994) . Furthermore, EGFR overexpression can cooperate with other tyrosine kinase receptors to induce cell transformation (Mullaney and Skinner, 1992) . These data suggest that the EGFR is one important factor for inducing tumorigenesis. However, the causal role played by the EGFR in the development of mammary tumors has yet to be de®ned.
We therefore set out to generate transgenic mice expressing the human EGFR under mammary gland speci®c promoters to test the hypothesis that the overexpression of the EGFR represents a primary event in inducing mammary tumors. We have generated independent transgenic mouse lines expressing the hEGFR cDNA under the control of the MMTV-LTR (MHERc) and the b-lactoglobulin promoter (BLGHERc), respectively. Hybrid genes comprising cDNAs are sometimes poorly expressed or are completely silent in transgenic animals. To circumvent these problems we used a transgene rescue approach (Yull et al., 1996) . The hEGFR cDNA was cloned into the pBJ41 û-lactoglobulin minigene-like expression construct and co-injected with the full length modi®ed, translational inactive genomic sequence of the û-lactoglobulin gene into fertilized oocytes. This transgene rescue is associated with transcription of the rescuing gene but does not require its translation and is thought to result in the co-activation of the EGFreceptor expression vector. In this regard, all transgenic lines generated with the BLGHERc constructs were double transgenic for both the pBJ41BLGHERc and the pBLGDtr.
The phenotype observed in the lactating mammary glands of BLGHERc and MHERc mice was similar indicating that the transgene eect is promoter independent. Surprisingly, we observed that there was impaired mammary epithelial development in virgin BLGHERc mice. This phenotype was characterized by multilayered ductal epithelium. It has been demonstrated that the WAP promoter can be activated in a subpopulation of mammary epithelial cells in the virgin gland even though its main expression occurs during lactation (Hennighausen et al., 1994) . If there exists a similar expression pattern for the BLG promoter, the human EGFR transgene could be expressed already during early development of the virgin mammary epithelium resulting in ductal hyperplasia.
Although the hEGFR transgene was expressed in salivary gland, ovary and testis of MHERc mice no apparent phenotypic changes were observed in these organs (data not shown). This is in contrast to other MMTV-v-Ha-ras, MMTV-c-neu and MMTV-heregulin transgenic mice that develop hyperplasias and/or tumors in these organs expressing the oncogenic transgene (Krane and Leder, 1996; Sinn et al., 1987) . Interestingly, in comparison to these animals the latency period in hEGFR overexpressing transgenic mice to develop dysplasias is longer and strongly correlated with the number of pregnancies. A potential explanation for these ®ndings is that, in the hEGFR transgenic mice, the level of hEGFR associated tyrosine kinase activity is below a certain threshold level of expression required for rapid transformation of mammary epithelial cells. In this respect, no tumors have been detected in virgin MHERc mice.
During involution, hEGFR expression driven by the BLG promoter is inactive while the expression driven by the MMTV-LTR promoter was relatively low as assessed, which we ascertained by immunohistochemistry and RT ± PCR. In this respect, we propose that many cells expressing high level of the hEGFR transgene are removed during involution. However, the histology of the regressed hEGFR transgenic mammary gland is dierent compared to regressed control mammary gland (Figure 3a2) . It is very similar to the histology of virgin transgenic mammary gland (Figure 3b,c) . Transgenic mammary glands of lactating MHERc and BLGHERc mice exhibit atrophic areas with increased labeling index and pronounced hEGFR Figure 7 WAP expression analysed by Northern blot analysis. 15 mg total RNA were puri®ed from second thoracic mammary gland of control and transgenic mice after 7 days in culture. WAP-and b-actin speci®c probes were employed. Tissue samples used in lanes 1 ± 4 are identical to a ± d in Figure 5 . Whole mount culture has been analysed. Lane 1: control gland cultured in lactogenic APIH-medium, lane 2: control gland cultured in lactogenic APIH-medium supplemented with 10 ng/ml mEGF, lane 3: MHERc transgenic gland (line 6903), and lane 4: BLGHERc transgenic (line 116), both cultured in lactogenic APIH-medium. Hybridization with an actin probe was used as control to normalize the WAP expression expression. The number of such areas containing ducts which lack free unobstructed lumens increases with the number of pregnancies. We conclude that these structures are not fully regressed during involution. It is possible that these hEGFR expressing atrophic areas accumulate during each successive pregnancy and may represent a potential stem cell population for malignant transformation.
The result from our transgenic study suggests that overexpression of the hEGFR in the mouse mammary gland can predispose animals to mammary epithelial cell transformation with a moderate degree of tumor development. Independent of the promoter used tumors develop stochastically after multiple pregnancies. EGF, one of the EGFR ligands, is transiently expressed during mammary gland development. This might restrict the proliferative stimulus of activated EGFR transgene exclusively to pregnancy and lactation. Taking into account that most of mammary epithelial cells undergo apoptosis after lactation it is not surprising that in hEGFR transgenic mice breast tumor development is correlated with the number of pregnancies. Cross breeding of hEGFR transgenic mice with other transgenic mice, such as TGF-a may con®rm this hypothesis. We would expect a reduction of latency period and enhanced tumor formation in these bi-transgenic mice.
This study demonstrates that overexpression of the hEGFR is an important factor in promoting mammary epithelial transformation. EGF blocks the dierentiation inducing eect of mammary derived growth inhibitor while stimulating monolayer growth and colony formation in soft-agar (Spitzer et al., 1995) . Furthermore, hEGFR overexpression can also block functional dierentiation in transgenic whole organ cultures. EGFR transgene overexpression inhibited ductal branching, development of lobulo-alveolar structures and WAP expression. In fact the morphology of the transgenic mammary gland is indistinguishable to wild type glands that have been cultured in lactogenic APIH-medium containing EGF. Therefore chronic stimulation of the EGFR pathway inhibits not only morphological dierentiation of the mammary gland, but also functional dierentiation while promoting epithelial cell proliferation, thereby facilitating cellular transformation and subsequent tumorigenesis. Additional genetic alterations are likely to contribute to the tumor phenotype in vivo in these hEGFR transgenic mice.
Materials and methods
DNA construction
Two constructs containing dierent mammary gland speci®c promoters driving the human EGFR cDNA were used for generating transgenic mice (Figure 1 ).
First, a 1.01 kb MMTV-LTR promoter/enhancer fragment was obtained by HincII/HindIII digestion from the pTG1 plasmid (kindly provided by Dr M Treuner, MDC-Berlin, Germany) and then cloned into the HindIII site of pBluescript plasmid (Stratagene, UK). The hEGFR cDNA linked to a SV 40 polyA + site was obtained by XbaI/SacII digestion from the CVN/HERc plasmid (kindly provided by Dr A Ullrich, Max-Planck-Institute, Munich, Germany). The resulting 4 kb hEGFR cDNA (HERc), was then cloned into MMTV/LTR-pBluescript vector at the XbaI and SacII, resulting in the plasmid named pMHERc.
Second, two dierent constructs based upon the û-lactoglobulin promoter (BLG) were used for a co-injection strategy (Yull et al., 1996) . The plasmid pBJ41 (kindly provided by Dr J Clark, Rosslin Institute, Edinburgh) is an intronless minigene derived from the 10.5 kb sheep BLG gene with an EcoRV site introduced into the 5' untranslated region (Whitelaw et al., 1991) . In brief, the hEGFR cDNA was cut as described above from the CVN/HERc plasmid vector and was ®lled in by Klenow (Life Technologies, UK). Following alkaline phosphatase treatment, the 4.0 kb fragment was inserted into the EcoRV site of the pBJ41 plasmid, resulting in the plasmid pBJ41BLGHERc (Archibald et al., 1990; Barash et al., 1994; McClenaghan et al., 1995; Yull et al., 1996) . All expression constructs were prepared from plasmid DNA as described previously (Theuring et al., 1995) .
The construct BLGdeltatrans (BLGDtr) which was coinjected with the pBJ41BLGHERc, was created from the BLG gene (10.5-kb SalI-XbaI-fragment pSSltgXS; (Simons et al., 1987) ) by PCR-mediated mutagenesis. One mutation was the insertion of a TC after ATGA, where ATG is the initiation codon. This creates a Bcl I restriction site and a frameshift, which renders a TGA 66 bp downstream of the initiation into a stop codon by putting it into reading frame. In addition, adenine, preceding this TGA, was changed to thymidine in order to destroy a potential in-frame reinitiation site which might have led to the production of a non-secreted BLG. The PCR-ampli®ed region was sequenced. Before establishing transgenic mice, the BLGdeltatrans (pBLGDtr) construct was stably transfected into HC11 mouse mammary epithelial cells. Western blotting of transfected HC11 cell extracts failed to detect any sheep BLG expression (data not shown).
Generation and identification of transgenic mice
For DNA microinjection, pMHERc was released by KpnI/ SacII digestion. The constructs pBJ 41BLGHERc and pBLGDtr were obtained from the plasmids by SalI/XbaI digestion. Outbred NMRI mice were used for microinjection. Transgenic mice were generated and identi®ed by previously described methods (Theuring et al., 1995) .
MHERc transgenic mice Transgene integration was analysed by PCR employing speci®c human EGFR primers: 5'-GAT CGG CCT CTT CAT GCG 3', position 2174 ± 2191 and 5'-TTC TTT CAT CCC CCT GAA TG-3', position 3126 ± 3146. This resulted in a characteristic band of about 1.0 kb.
BLGHERc transgenic mice In parallel to speci®c human EGFR primers, speci®c sheep û-lactoglobulin primers were used for PCR analysis: 5'-GCT TCT GGG GTC TAC CAG GAA-3', position 579 ± 599, and 5'-TCG TGC TTC TGA GCT CTG CA-3', position 806 ± 825, resulting in a 240 bp DNA band. Mice that were positive for both hEGFR and sheep û-lactoglobulin sequences was considered to bitransgenic.
RT ± PCR and Northern blot analysis
Expression analysis in transgenic mice was performed by reverse transcription RT ± PCR and Northern blot analysis. RNA was prepared by a single step method (Chomczynski and Sacchi, 1987) . For RT ± PCR analysis 25 mg of total RNA were converted to cDNA by reverse transcriptase (Life Technologies, UK). The PCR was performed as described before using ampliTaq DNA polymerase (Life Technologies, UK). For Northern analysis RNA was separated on a 1.25% agarose formaldehyde gel and transferred to a hybond N nylon membrane (Amersham). To detect speci®c transcripts, 32 P-labeled cDNA probes were used for hybridization on the membranes. A 1.0 kb WAP cDNA fragment (kindly provided by Dr M Treuner, Max DelbruÈ ck Center, Berlin, Germany) was used for analysing WAP expression. For transgene expression a 1.8 kb hEGFR speci®c cDNA fragment was used.
Histological evaluation
Tissue for histology and immunohistology was ®xed in 10% buered formalin, embedded in paran, sectioned at 4 mm and stained with hematoxilin and eosin. The number of ducts was counted under the microscope (100-fold enlargement). Five random ®elds (microscopic views) were selected for one data point.
Immunohistochemistry
For hEGFR protein detection, paran embedded tissue was sectioned at 4 mm and deparanized. Immunostaining was performed using a biotin-streptavidin ampli®ed detection system (Amersham, Germany). The hEGFR was detected speci®cally using a sheep anti-hEGFR peptide speci®c polyclonal antibody (Amersham, Germany). For antibody binding detection, a peroxidase (POD) conjugated secondary antibody combined with the metal enhanced DAB system was used (Pierce, UK). PCNA staining was performed using the AB-1 monoclonal antibody (Oncogene Science, CA USA). As described above, the POD system was used for detection (®ve microscopic ®elds were counted for labeled nuclei). All sections were counterstained with Meyer's hematoxilin.
Whole mount staining
Whole-mounted mammary glands were ®xed in Ethanol/ CHCl 3 /acetic acid (6 : 3 : 1), rehydrated and stained in carmine red solution [0.2% carmine red dye (w/v), 10 mM AlK(SO 4 ) 2 ]. After staining the slides are dehydrated and the glands were cleared with xylene and stored in methyl salicylate.
Whole mount organ culture
To culture whole second thoracic mammary glands of estradiol and progesterone-primed virgin mice in serum-free medium, we adapted the original protocol with minor modi®cations (Banerjee et al., 1973) . Four 6 week-old virgin female NMRI mice were injected subcutaneously for 9 consecutive days with progesterone (1 mg) and estradiol (1 mg) (Sigma Chemicals Co., St. Louis, MO, USA) dissolved in gum arabicum/0.9% NaCl. The second pair of thoracic glands, including the primary duct, were excised and cultivated for 7 days on perforated cyclopore membranes (Falcon Plastics, Cocksville, MD, USA) in 2 ml medium 199 with Hank's salts (GIBCO, BRL, Gaithersburgh, MD, USA), gentamycin (40 mg/ml), aldosterone, bovine prolactin, insulin (each at 5 mg/ml: Sigma), and hydrocortisone (1 mg/ml: Merck, Darmstadt, Germany), referred to as APIH lactogenic medium. For some experiments hEGF (10 ng/ml: Sigma Chemicals Co., St. Louis, MO, USA) was added to the APIH medium. Culture medium was changed every 2 days. Three pairs of contralateral glands were examined routinely, one gland was used as control. Formalin-®xed whole glands were stained with hematoxilin as described (Rivera, 1967) .
